Triple-negative breast cancer: Future prospects in diagnosis and management

Medical Oncology

Volumn 31, Issue 2, 2014, Pages

  Elsamany, Shereef ^a,b   Abdullah, Sakher ^a  

^a King Abdullah Medical City ^*  (Saudi Arabia)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Breast; Diagnosis; Future; Management; Triple negative

Indexed keywords

ANDROGEN RECEPTOR; ANTIMITOTIC AGENT; BETA CATENIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE P60;

BASAL LIKE BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CELL ADHESION; CELL CYCLE; CELL DIVISION; CELL MOTILITY; CELL PROLIFERATION; HUMAN; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; DISEASE MANAGEMENT; FEMALE; PROGNOSIS;

DISEASE MANAGEMENT; FEMALE; HUMANS; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84891444836     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0834-y     Document Type: Review

References (33)

1. Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-92.
2. Dent R, Trudeau M, Pritchard K, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-48.
4. Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012:217185, 1-7.
5. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies. J Clin Investig. 2011;121(7):2750-67.
6. Bauer JA, Chakravarthy AB, Rosenbluth JM, et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res. 2010;16(2):681-90.
7. Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:486.
8. Adamo B, Anders CK. Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res. 2011;13:105.
9. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13:R21.
10. Tutt A, Robson M, Garber JE, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of concept trial. Lancet. 2010;376(9737):235-44.
11. Ibrahim Y, Garcia C, Serra V, et al. PI3Kinhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2:1036-47.
12. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26:3785-90.
13. Lord CJ, Garrett MD, Ashworth A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res. 2006;12:4463-8.
14. Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2:1048-63.
15. Collins LC, Cole K, Marotti J, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol. 2011;24(7):924-31.
16. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triplenegative breast cancer subtypes and preclinicalmodels for selection of targeted therapies. J Clin Investig. 2011;121(7):2750-67.
17. Lehmann BD, Bauer JA, Schafer JM, et al. Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer. Cancer Res. 2012; 72(24 Suppl 3): Abstract P6-05-03.
18. King TD, Suto MJ, Li Y. The Wnt/b-catenin signalling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2012;113:13-8.
19. Yang L, Kim C, Yen Y. FZD7 in triple negative breast cancer cells. In: Mehmet Gunduz, editor. Breast cancer-carcinogenesis, cell growth and signalling pathways. Shanghai: In Tech; 2011. p. 551-62.
20. Yang L, Wu X, Wang Y, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011; 43:4437-46.
21. Rey JP, Ellies DL. Wnt modulators in the biotech pipeline. Dev Dyn. 2010;239(1):102-14.
22. Liu J, Pan S, Sun F, et al. Targeting porcupine, a critical node for Wnt signalling in cancer. Cancer Res. 2011;71(24 Suppl 3): Abstract PD08-11.
23. Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008;19: 1379-86.
24. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105(3): 319-26.
25. Tryfonopoulos D, Walsh S, Collins DM, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011;22(10):2234-40.
26. Huang F, Reeves K, Han X, et al. Identification of candidate molecularmarkers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67:2226-38.
27. Rugo H, Keck S. Reversing hormone resistance: have we found the golden key? JCO. 2012;30:22.
28. Deonarain MP, Kousparou C, Epenetos A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs. 2009;1(1):12-25.
29. Yu X, Lin Y, Yan X, et al. CD133, stemcells, and cancer stem cells: myth or reality? Curr Colorectal Cancer Rep. 2011;7:253-9.
30. Lu D, Choi M, Yu J, et al. Salinomycin inhibits Wnt signalling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011;108:13253-7.
31. Tang QL, Zhao ZQ, Li JC, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011;311(1):113-21.
32. Martelli AM, Evangelisti C, Chiarini F, et al. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers. 2010;2:1576-96.
33. Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signalling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci. 2009;106:268-73.